BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31300052)

  • 21. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.
    Pallandre JR; Brillard E; Créhange G; Radlovic A; Remy-Martin JP; Saas P; Rohrlich PS; Pivot X; Ling X; Tiberghien P; Borg C
    J Immunol; 2007 Dec; 179(11):7593-604. PubMed ID: 18025205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity.
    Vo MC; Lee HJ; Kim JS; Hoang MD; Choi NR; Rhee JH; Lakshmanan VK; Shin SJ; Lee JJ
    Oncotarget; 2015 Oct; 6(32):33781-90. PubMed ID: 26418952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Regulation of Toll-Like Receptor 2 Engagement on CD4
    Wu XZ; Zhou Q; Lin H; Zhai K; Wang XJ; Yang WB; Shi HZ
    Am J Respir Cell Mol Biol; 2017 Mar; 56(3):342-352. PubMed ID: 27767332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secreted heat shock protein 90alpha induces colorectal cancer cell invasion through CD91/LRP-1 and NF-kappaB-mediated integrin alphaV expression.
    Chen JS; Hsu YM; Chen CC; Chen LL; Lee CC; Huang TS
    J Biol Chem; 2010 Aug; 285(33):25458-66. PubMed ID: 20558745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of plasma LC3B
    Chen YQ; Zheng L; Zhou J; Wang P; Wang L; Zhang Y; Man ZS; Chen YH; Gu F; Niu GP
    Int Immunopharmacol; 2022 Jul; 108():108760. PubMed ID: 35398623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toll-like receptor 2 suppresses immunity against Candida albicans through induction of IL-10 and regulatory T cells.
    Netea MG; Sutmuller R; Hermann C; Van der Graaf CA; Van der Meer JW; van Krieken JH; Hartung T; Adema G; Kullberg BJ
    J Immunol; 2004 Mar; 172(6):3712-8. PubMed ID: 15004175
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Kim WS; Jung ID; Kim JS; Kim HM; Kwon KW; Park YM; Shin SJ
    Front Cell Infect Microbiol; 2018; 8():95. PubMed ID: 29637049
    [No Abstract]   [Full Text] [Related]  

  • 28. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling.
    Zanin-Zhorov A; Cahalon L; Tal G; Margalit R; Lider O; Cohen IR
    J Clin Invest; 2006 Jul; 116(7):2022-32. PubMed ID: 16767222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells.
    Zhou X; Su YX; Lao XM; Liang YJ; Liao GQ
    Oral Oncol; 2016 Feb; 53():27-35. PubMed ID: 26631955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates.
    Zom GG; Khan S; Britten CM; Sommandas V; Camps MG; Loof NM; Budden CF; Meeuwenoord NJ; Filippov DV; van der Marel GA; Overkleeft HS; Melief CJ; Ossendorp F
    Cancer Immunol Res; 2014 Aug; 2(8):756-64. PubMed ID: 24950688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toll-like receptor ligands directly promote activated CD4+ T cell survival.
    Gelman AE; Zhang J; Choi Y; Turka LA
    J Immunol; 2004 May; 172(10):6065-73. PubMed ID: 15128790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-derived autophagosomes (DRibbles) induce B cell activation in a TLR2-MyD88 dependent manner.
    Li W; Zhou M; Ren H; Hu HM; Lu L; Cao M; Wang LX
    PLoS One; 2013; 8(1):e53564. PubMed ID: 23326458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of cross-priming of naive CD8+ T lymphocytes by recombinant bacillus Calmette-Guerin that secretes heat shock protein 70-major membrane protein-II fusion protein.
    Mukai T; Maeda Y; Tamura T; Matsuoka M; Tsukamoto Y; Makino M
    J Immunol; 2009 Nov; 183(10):6561-8. PubMed ID: 19846882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
    Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
    J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Roles of lipoxin A4 receptor activation and anti-interleukin-1β antibody on the toll-like receptor 2/mycloid differentiation factor 88/nuclear factor-κB pathway in airway inflammation induced by ovalbumin.
    Kong X; Wu SH; Zhang L; Chen XQ
    Mol Med Rep; 2015 Jul; 12(1):895-904. PubMed ID: 25760938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro.
    Liu H; Zhang G; Huang J; Ma S; Mi K; Cheng J; Zhu Y; Zha X; Huang W
    J Transl Med; 2016 Apr; 14(1):104. PubMed ID: 27118139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A; Aruga E; Cameron MJ; Chang AE
    J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4+ T Cell Help Is Mandatory for Naive and Memory Donor-Specific Antibody Responses: Impact of Therapeutic Immunosuppression.
    Chen CC; Koenig A; Saison C; Dahdal S; Rigault G; Barba T; Taillardet M; Chartoire D; Ovize M; Morelon E; Defrance T; Thaunat O
    Front Immunol; 2018; 9():275. PubMed ID: 29515582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epicutaneous immunization induces alphabeta T-cell receptor CD4 CD8 double-positive non-specific suppressor T cells that inhibit contact sensitivity via transforming growth factor-beta.
    Szczepanik M; Bryniarski K; Tutaj M; Ptak M; Skrzeczynska J; Askenase PW; Ptak W
    Immunology; 2005 May; 115(1):42-54. PubMed ID: 15819696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
    Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
    J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.